Cleerly LABS vs EchoSolv AS

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Cleerly
VS
by Echo IQ

AI Verdict

Cleerly LABS focuses on analyzing CCTA images to assess coronary artery disease, including plaque and stenosis, for personalized heart attack prevention. In contrast, EchoSolv AS analyzes echocardiogram measurements to identify patients at high risk for severe aortic stenosis. While both are cardiology AI tools, they target different cardiac conditions and utilize distinct diagnostic inputs, making them suitable for different clinical pathways.

Choose Cleerly LABS if…

Choose Cleerly LABS if you require a comprehensive, AI-powered analysis of coronary CT angiography (CCTA) images to precisely quantify and characterize atherosclerosis and stenosis. This tool is ideal for clinicians focused on personalized heart disease management, tracking disease progression over time, and gaining detailed 3D visualizations of coronary arteries.

View Cleerly LABS →

Choose EchoSolv AS if…

Choose EchoSolv AS if your primary need is rapid, AI-powered clinical decision support to identify patients at high risk for severe aortic stenosis from existing echocardiogram measurements. This platform is best suited for streamlining workflows by providing ultra-fast risk detection and second-reader support, without requiring direct EMR integration.

View EchoSolv AS →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Cleerly LABS EchoSolv AS
Pricing Per analysis Unknown
Deployment Cloud-based (AWS), web-based application, with on-site Cleerly Proxy for data transfer. Cloud-based
BAA Available Yes AI-estimated Yes AI-estimated
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoSolv AS

EchoSolv AS emphasizes seamless integration into existing workflows without requiring EMR integration, which often simplifies deployment and user adoption. Its measurement-based AI and ultra-fast detection (under 3 seconds) suggest a highly streamlined and efficient user experience. Cleerly LABS, while powerful, involves comprehensive image analysis and a data transfer proxy, potentially introducing more complexity for the user.

Clinical Value

Cleerly LABS

Cleerly LABS offers a comprehensive and longitudinal assessment of coronary artery disease, including detailed plaque characterization, stenosis quantification, ischemia detection, personalized risk assessment, and the ability to track disease progression over time. This broad and ongoing insight into CAD provides a higher overall clinical value for personalized heart disease management compared to EchoSolv AS's focused detection of severe aortic stenosis.

Pricing & Value

Cleerly LABS

Cleerly LABS provides transparent per-analysis pricing and has established CPT codes for its plaque and ischemia analysis, which simplifies the reimbursement process for providers and offers a clearer financial value proposition. EchoSolv AS's pricing relies on a miscellaneous reimbursement code and a subscription model, with a less established reimbursement pathway currently under development for a Category III CPT code.

Enterprise Readiness

Cleerly LABS

Both tools are FDA-cleared, HIPAA compliant, cloud-based, and offer BAAs, demonstrating strong foundational enterprise readiness. However, Cleerly LABS explicitly supports broader integration with PACS, RIS, and EHR systems via its Cleerly Proxy, indicating a more comprehensive strategy for integrating into a hospital's full IT ecosystem. EchoSolv AS's explicit 'no EMR integration required' might simplify initial deployment but could limit deeper enterprise-wide data flow.

Innovation

Cleerly LABS

Cleerly LABS' innovation lies in its comprehensive, quantitative, and longitudinal assessment of atherosclerosis from CCTA, including detailed plaque characterization and progression tracking, aiming to 'create a new standard of care' for heart disease. While EchoSolv AS offers an innovative measurement-based AI approach for efficient aortic stenosis detection, Cleerly's ambition to redefine CAD management through deeper insights represents a more transformative innovation in cardiovascular imaging.

Support & Docs

EchoSolv AS

EchoSolv AS provides a more robust and transparent offering for support and documentation, including a dedicated 'Trust Center' with downloadable SOC 2 Type II and HIPAA audit reports, as well as a referenced clinician user manual. While Cleerly offers client support and billing resources, EchoSolv AS's public availability of detailed compliance and user documentation gives it an edge.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Cleerly LABS EchoSolv AS
Name Cleerly LABS EchoSolv AS
Company Cleerly Echo IQ
Primary Focus Comprehensive analysis of coronary CT angiography (CCTA) to detect, quantify, and characterize atherosclerosis and stenosis, aiding in personalized heart disease management. Identify patients at risk for severe aortic stenosis with high accuracy and efficiency.
Input Data Type CCTA images (AI-powered CCTA image analysis) Numerical measurements (analyzes numerical measurements, not images)
Key Output/Analysis Comprehensive coronary plaque assessment (volume, type), Stenosis detection and quantification, Ischemia detection (with Cleerly ISCHEMIA module), 3D visualization, Personalized heart disease risk assessment, Tracking disease progression. AI-powered clinical decision support for severe aortic stenosis probability, Consistent severe AS probability and guideline check, Second reader support, Ultra-fast risk detection (under 3 seconds).
Integration Capabilities Integration with PACS, RIS, EHR via Cleerly Proxy. Designed to fit existing workflows (no EMR integration required, integrates with PACS).

Videos

Demos, reviews, and walkthroughs featuring Cleerly LABS and EchoSolv AS.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Cleerly LABS is designed for comprehensive analysis of coronary CT angiography (CCTA) to detect, quantify, and characterize atherosclerosis and stenosis, aiding in personalized heart disease management. EchoSolv AS focuses on analyzing echocardiograms to identify patients at risk for severe aortic stenosis with high accuracy and efficiency.
Cleerly LABS directly analyzes coronary CT angiography (CCTA) images to provide its insights into coronary plaque and stenosis. In contrast, EchoSolv AS analyzes numerical measurements derived from echocardiograms, rather than the raw images themselves, to assess severe aortic stenosis probability.
Cleerly LABS integrates with PACS, RIS, and EHR systems via an on-site Cleerly Proxy for data transfer. EchoSolv AS is designed to fit existing workflows, integrating with PACS, and explicitly states that no EMR integration is required.
No, their features are distinct based on their clinical focus. Cleerly LABS offers comprehensive coronary plaque assessment, stenosis detection, 3D visualization, and personalized heart disease risk assessment from CCTA. EchoSolv AS provides AI-powered clinical decision support for severe aortic stenosis probability, a guideline check from echo measurements, and second reader support.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.